Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of b/Yamagata

Pediatric Infectious Disease Journal

Volumn 30, Issue 10, 2011, Pages 833-839

  Skowronski, Danuta M ^a,b   Hottes, Travis S ^a   De Serres, Gaston ^c   Ward, Brian J ^d   Janjua, Naveed Z ^a,b   Sabaiduc, Suzana ^a   Chan, Tracy ^a   Petric, Martin ^a  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

child; children; immunology; infants; influenza; influenza vaccine; influenza vaccines administration and dosage; influenza vaccines immunology

Indexed keywords

INFLUENZA VACCINE; HEMAGGLUTININ FUSOGENIC PEPTIDE, INFLUENZA VIRUS; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ; VIRUS RNA;

ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INFANT; INFLUENZA; MAJOR CLINICAL STUDY; MICROBIOLOGICAL PARAMETERS; MICRONEUTRALIZATION ASSAY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SEROPROTECTION RATE; TITRIMETRY; TREATMENT OUTCOME; BLOOD; DNA SEQUENCE; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA VIRUS B; METHODOLOGY; MOLECULAR GENETICS; VACCINATION;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; INFLUENZA B VIRUS; INFLUENZA VACCINES; MOLECULAR SEQUENCE DATA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VACCINATION; VACCINES, INACTIVATED;

EID: 80052925426     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31822db4dc     Document Type: Article

References (22)

1. Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175:59-68. (Pubitemid 20093061)
2. Shaw MW, Xu X, Li Y, et al. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons [rapid communication]. Virology. 2002;303:1-8. (Pubitemid 36027160)
3. National Advisory Committee on Immunization [NACIl Statement on seasonal trivalent inactivated influenza vaccine (TIV) for the 2009-2010 season. Can Commun Dis Rep 2009;35:1-41. Available at: http://origin phac-aspc.gc.ca/ publicat/ccdr-rmtc/09pdf/acs-dcc-06.pdf Accessed April 3, 2011.
4. National Advisory Committee on Immunization [NACIl Statement on seasonal trivalent inactivated influenza vaccine (TIV) for the 2010-2011 season. Can Commun Dis Rep 2010, 36: 1-49. Available at: http://www.phac-aspc.gc. ca/publicat/ccdr-rmtc/10pdf/36-acs-6.pdf Accessed April 3 2011.
5. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009;58(No. RR-8):1-52. Available at: http://www.cdc.gov/mmwr/pdf/rr/rr5808.pdf Accessed April 3, 2011.
6. Levandowski RA, Gross PA, Weksler M, Staton E, Williams MS, Bonelli J. Cross-reactive antibodies induced by a monovalent influenza B virus vaccine. J Clin Microbiol. 1991;29:1530-1532.
7. Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6-to 23-month-old children: are identical antigens necessary for priming? Pediatrics. 2006;118:e570-e578. (Pubitemid 46091608)
8. Englund JA, Walter EB, Gbadebo A, et al. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006;118:e579-e585. (Pubitemid 46091609)
9. Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics. 2011 Jul 18. [Epub ahead of print].
10. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(No. RR-8):1-62. Available at: http://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf. Accessed April 3, 2011.
11. Monto AS, Maassab F. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol. 1981;13:54-57. (Pubitemid 11176658)
12. Karber G. Beitrag zur Kollektiven Behandling Pharmakologischer Reihen-versuche. Arch Exp Path Pharmakol. 1931;162:480-483.
13. Committee for Proprietary Medicinal Products [CPMP]. Note for guidance on harmonization of requirements for influenza vaccines. London, UK: European Agency for the Evaluation of Medicinal Products. 1997, March 17. CPMP/BWP/214/96(circular no. 96-0666) 1-22. Available at: http://www.emea. europa.eu/pdfs/human/bwp/021496en.pdf Accessed April 3,2011.
14. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35:69-75. (Pubitemid 9096975)
15. Kendal AP, Cate TR. Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol. 1983;18:930-934. (Pubitemid 13005425)
16. Kim JH, Skountzou I, Compans R, et al. Original antigenic sin responses to influenza viruses. J Immunol. 2009;183:3294-3301.
17. Morens DM, Burke DS, Halstead SB. The wages of original antigenic sin. Emerg Infect Dis. 2010;16:1023-1024.
18. Public Health Agency of Canada. FluWatch Weekly Reports 2008-2009 Season. Available at: http://www.phac-aspc.gc.ca/fluwatch/08-09/index-eng.php. Accessed April 3, 2011.
19. Public Health Agency of Canada (PHAC). FluWatch Weekly Reports 2009-2010 Season. 2010. Available at: http://www.phac-aspc.gc.ca/fluwatch/09-10/index-eng. php. Accessed April 3, 2011.
20. Public Health Agency of Canada (PHAC). FluWatch Weekly Reports 2010-2011 Season. 2011. Available at: http://www.phac-aspc.gc.ca/fluwatch/10-11/index-eng. php. Accessed April 3, 2011.
21. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010;28(suppl 4):D45-D53.
22. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA. 2009;106:8701-8706.